101 related articles for article (PubMed ID: 12407131)
1. In vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans.
Dhople AM; Namba K
J Antimicrob Chemother; 2002 Nov; 50(5):727-9. PubMed ID: 12407131
[TBL] [Abstract][Full Text] [Related]
2. Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice.
Dhople AM; Namba K
J Chemother; 2003 Feb; 15(1):47-52. PubMed ID: 12678414
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
Dhople AM
Int J Antimicrob Agents; 2001 Jan; 17(1):57-61. PubMed ID: 11137650
[TBL] [Abstract][Full Text] [Related]
4. In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae.
Dhople AM; Namba K
J Infect Chemother; 2003 Mar; 9(1):12-5. PubMed ID: 12673400
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans.
Thangaraj HS; Adjei O; Allen BW; Portaels F; Evans MR; Banerjee DK; Wansbrough-Jones MH
J Antimicrob Chemother; 2000 Feb; 45(2):231-3. PubMed ID: 10660507
[TBL] [Abstract][Full Text] [Related]
6. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.
Dhople AM; Namba K
Int J Antimicrob Agents; 2003 Mar; 21(3):251-5. PubMed ID: 12636987
[TBL] [Abstract][Full Text] [Related]
7. In vivo susceptibility of Mycobacterium ulcerans to KRM-1648, a new benzoxazinorifamycin, in comparison with rifampicin. Anti-mycobacterial activity of KRM-1648.
Dhople AM
Arzneimittelforschung; 2001; 51(6):501-5. PubMed ID: 11455683
[TBL] [Abstract][Full Text] [Related]
8. Sitafloxacin (DU-6859a) and trovafloxacin: postantibiotic effect and in vitro interactions with rifampin on methicillin-resistant Staphylococcus aureus.
Giamarellou-Bourboulis EJ; Sambatakou H; Grecka P; Chryssouli Z; Giamarellou H
Diagn Microbiol Infect Dis; 1999 Aug; 34(4):301-7. PubMed ID: 10459481
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Tomioka H; Sato K; Akaki T; Kajitani H; Kawahara S; Sakatani M
Antimicrob Agents Chemother; 1999 Dec; 43(12):3001-4. PubMed ID: 10582897
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex.
Tomioka H; Sano C; Sato K; Shimizu T
Int J Antimicrob Agents; 2002 Feb; 19(2):139-45. PubMed ID: 11850167
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans.
Dhople AM
J Antimicrob Chemother; 2001 Jan; 47(1):93-6. PubMed ID: 11152437
[TBL] [Abstract][Full Text] [Related]
12. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice.
Dega H; Bentoucha A; Robert J; Jarlier V; Grosset J
Antimicrob Agents Chemother; 2002 Oct; 46(10):3193-6. PubMed ID: 12234844
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
[TBL] [Abstract][Full Text] [Related]
14. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study.
O'Brien DP; McDonald A; Callan P; Robson M; Friedman ND; Hughes A; Holten I; Walton A; Athan E
PLoS Negl Trop Dis; 2012 Jan; 6(1):e1473. PubMed ID: 22272368
[TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of three new fluoroquinolones and synergy with ansamycins against Mycobacterium leprae.
Dhople AM; Ibanez MA
J Antimicrob Chemother; 1993 Sep; 32(3):445-51. PubMed ID: 8262866
[TBL] [Abstract][Full Text] [Related]
16. Anti-Mycobacterium tuberculosis activities of new fluoroquinolones in combination with other antituberculous drugs.
Tomioka H; Sato K; Shimizu T; Sano C
J Infect; 2002 Apr; 44(3):160-5. PubMed ID: 12099742
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of Mycobacterium ulcerans to a combination of amikacin/rifampicin.
Marsollier L; Prévot G; Honoré N; Legras P; Manceau AL; Payan C; Kouakou H; Carbonnelle B
Int J Antimicrob Agents; 2003 Dec; 22(6):562-6. PubMed ID: 14659652
[TBL] [Abstract][Full Text] [Related]
18. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
Bhusal Y; Shiohira CM; Yamane N
Int J Antimicrob Agents; 2005 Oct; 26(4):292-7. PubMed ID: 16150578
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium.
Sano C; Tatano Y; Shimizu T; Yamabe S; Sato K; Tomioka H
Int J Antimicrob Agents; 2011 Apr; 37(4):296-301. PubMed ID: 21353489
[TBL] [Abstract][Full Text] [Related]
20. Evaluating decontamination protocols for the isolation of Mycobacterium ulcerans from swabs.
Owusu E; Newman MJ; Akumwena A; Bannerman E; Pluschke G
BMC Microbiol; 2017 Jan; 17(1):2. PubMed ID: 28056807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
